| Prev Close | 165.47 |
| Day Low/High | 165.58 / 166.81 |
| 52 Wk Low/High | 94.82 / 165.95 |
Alexion Pharmaceuticals, Inc. (ALXN)
166.54
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 220.92B |
| Market Cap | 36.56B |
| P/E Ratio | 37.32 |
| Div & Yield | N.A. (N.A) |
Rules of the Game: Further on Free Cash Flow
This metric is a prime indicator of financial health, and these health-related stock stand out.
Fitz Bits: Google Primed to Buy
The stock may now be at a tradable low -- but keep your stop tight.
Two Pharma Stocks Enjoying Good Health
These large-cap companies have topped expectations for four quarters and are projected to again report robust earnings.
Healthcare Holds Firm
The entire sector did well withstanding Tuesday's decline, but here are a few standouts.
Fitz Bits: A Stalwart Uptrend
Use this Alexion pullback as a buying opportunity.
The Week Ahead: GDP Data, Earnings
Contributor Ken Shreve takes a look at economic data and earnings reports scheduled for this week.
Biotech Is a Source of Buys
Alexion shows one of the most bullish long-term charts in my database.
Daily Recap of the Charts June 15
Mark Sperling of T3Live review the day's market action and sets up your trading plan for the next session.
Big-Cap Health Care Winners
Alexion Pharmaceuticals and Intuitive Surgical are leaders in a top-performing sector.
Sitting Tight for Respectable Volume
The light volume keeps me hesitant, though here are a few recent standout names.
Bull Market in Biotech
The biotechnology sector has weathered the correction and looks ready to push higher.
Fitz Bits: More Quick Bites
Here's another serving of buy-on-the-bounce trades
Mo-Mos Lose Their Mojo
Momentum stocks are under fairly severe pressure.
The Week Ahead: Housing Data, GDP and Earnings
Contributor Ken Shreve takes a look at economic data and earnings reports scheduled for the coming week.
Not for the Faint of Heart
The high-fliers I have been showing can reap huge returns, but make sure you can handle the volatility.
Fitz Bits: Stay Long Alexion
The shares are highly likely to test $100. Just keep a trailing stop on any existing positions.
Look for Resting Stocks
The virtuous cycle of overrunning price targets is in effect.
The Cure for Alexion
With only one drug on the market, the pharmaceutical company is expanding its pipeline.
The Day Ahead: Pulling Back
News that Greece will need further austerity measures dragged down world markets and U.S. futures.
